Pyxis Oncology, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum
Pyxis Oncology, Inc. (PYXS) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum of 103.00% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum · last filed 2026-08-13
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2026-03-31 was 103.00%, a 3.09% increase year-over-year.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2025-09-30 was 99.03%.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2025-06-30 was 101.51%, a 1.17% increase year-over-year.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2025-03-31 was 99.91%, a 2.31% decline year-over-year.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2025 was 101.51%, a 0.74% decline from fiscal 2024.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2024 was 102.27%, a 13.99% decline from fiscal 2023.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2023 was 118.90%, a 16.96% increase from fiscal 2022.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2022 was 101.66%, a 1.69% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 12 month |
|---|---|---|---|---|
| 2026-06-30 | 103.00% 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | 103.00% 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | 101.51% 10-K · filed 2026-03-23 | |||
| 2025-09-30 | 99.03% 10-Q · filed 2025-11-03 | 101.51% 10-Q · filed 2025-11-03 | ||
| 2025-06-30 | 101.51% 10-Q · filed 2026-08-13 | 101.51% 10-Q · filed 2026-08-13 | ||
| 2025-03-31 | 99.91% 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | 102.27% 10-K · filed 2026-03-23 | |||
| 2024-09-30 | 102.27% 10-Q · filed 2025-11-03 | |||
| 2024-06-30 | 100.34% 10-Q · filed 2025-08-14 | 102.27% 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | 102.27% 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | 118.90% 10-K · filed 2025-03-18 | |||
| 2023-09-30 | 118.90% 10-Q · filed 2024-11-12 | 118.90% 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | 97.82% 10-Q · filed 2024-08-14 | |||
| 2022-12-31 | 101.66% 10-K · filed 2024-03-21 | |||
| 2022-09-30 | 97.34% 10-Q · filed 2023-11-07 | 101.66% 10-Q · filed 2023-11-07 | ||
| 2022-06-30 | 101.63% 10-Q · filed 2023-08-11 | 101.66% 10-Q · filed 2023-08-11 | ||
| 2022-03-31 | 101.66% 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | 103.41% 10-K · filed 2023-03-22 | |||
| 2021-09-30 | 73.13% 10-Q · filed 2022-11-01 | 75.17% 10-Q · filed 2022-11-01 | ||
| 2020-12-31 | 87.40% 10-K · filed 2022-03-29 | |||
| 2020-09-30 | 87.40% 10-Q · filed 2021-11-15 | 87.40% 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |